Michael Hofman, FRACP, MBBS, explores the evolving landscape of imaging techniques in the diagnosis and treatment of renal cell carcinoma, particularly focusing on PET-CT scans. Historically underutilized in renal cancer, similar to the early days of prostate cancer imaging, PET-CT is gaining traction with new radiotracers improving patient outcomes. Hofman highlights the use of PSMA and FAPI tracers, their uptake in renal cancer, and the innovative use of the zirconium-89 labeled antibody targeting CA9 in large-scale trials. Additionally, the shift from antibodies to small molecules is examined, showcasing potential benefits in tumor detection and patient convenience in renal cell carcinoma imaging.